VVD-130037 + docetaxel

VVD-130037 + docetaxel is an investigational combination therapy being evaluated in clinical trials for advanced solid tumors. VVD-130037 is a small molecule, oral, covalent activator of Kelch-like ECH-associated protein 1 (KEAP1), leading to degradation of nuclear factor-erythroid 2 p45-related factor 2 (NRF2). Docetaxel is a well-established microtubule inhibitor used as chemotherapy. The rationale for the combination is to enhance antitumor activity in advanced solid malignancies by simultaneously disrupting the KEAP1-NRF2 pathway—a key regulator of cellular response to oxidative stress, frequently dysregulated in cancer—and microtubule dynamics. VVD-130037 is developed by Vividion Therapeutics, an independently operated subsidiary of Bayer. As of the most recent data, this combination is in Phase 1 clinical evaluation for advanced solid tumors, with VVD-130037 administered orally and docetaxel by intravenous infusion[4][6][10].